Targeting of Cxcr1 With Ketoprofen As A Novel Therapeutic Approach For Bipolar and Schizophrenia Diseases

Background and aim: bipolar and schizophrenia are prevalent psychotic disorders that characterized by impairment in the emotions and cognition. since molecular mechanism of these diseases are still unknown, most therapeutic approaches only reduce symptoms. today, in silico analysis play an important role in the molecular mechanism detection of disease and finding the correct therapeutic targets. methods: the rna seq data of brain tissue associated to patients harboring bipolar and schizophrenia (gse80655) diseases were selected from gene expression omnibus. differentially expressed genes (degs) were extracted by deseq package in r software. data were chosen based on log>1 and p adjusted value <0.05. the protein-protein interaction (ppi) network of degs was determined by string database and further analyzed through cytoscape software. subsequently, the interacted drugs with the hub genes were determined by genecards database. results: our functional analysis showed that genes were highly expressed in the bipolar and schizophrenia participated in cytokine-cytokine receptor interaction pathway. the ppi analysis also indicated cxcr1 gene was commonly expressed in both disorders and displayed more interactions with other genes. we additionally showed that ketoprofen as an inflammatory drug inhibited this gene activity. conclusion: in general, inflammation possesses an important role in the pathogenesis of bipolar and schizophrenia diseases. this study suggested genes that regulate the inflammatory pathways which could be introduced as potential therapeutic targets for treatment of these diseases.